Aquestive Therapeutics, Inc. (AQST) stock
AQSTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.70−0.06 (-1.60%)
Close on Nov 17, 2026Market cap $464.39MP/E –Yield –
Aquestive Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Aquestive Therapeutics's enterprise value was $401.53M on Nov 11, 2026, against $624.00M a year earlier. Over the last 5 years it ranged from $11.89M to $656.85M, with a median of $216.91M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $401.53M | -38.9% |
| 2025 | Dec 31, 2025 | $656.85M | +166.3% |
| 2024 | Dec 31, 2024 | $246.70M | +124.5% |
| 2023 | Dec 29, 2023 | $109.90M | +267.2% |
| 2022 | Dec 30, 2022 | $29.93M | -76.0% |
| 2021 | Dec 31, 2021 | $124.76M | -23.4% |
| 2020 | Dec 31, 2020 | $162.80M | +30.4% |
| 2019 | Dec 31, 2019 | $124.84M | +34.0% |
| 2018 | Dec 31, 2018 | $93.15M | – |
See a number that looks wrong?